Kyverna rises as cell therapy shows durable benefit in rare nerve disease

Kyverna Therapeutics

24/09/2026 12:21

** Shares of biotech firm Kyverna Therapeutics KYTX.O rise 6.1% to $7.50 premarket
** Co says its experimental cell therapy, miv-cel, delivered sustained benefit through one year in stiff person syndrome, a rare disease causing severe muscle stiffness and spasms
** 95% of patients who achieved meaningful mobility improvement maintained that benefit at one year; 92% remained off chronic immunotherapy
** Says 67% of patients who needed walking aids before treatment no longer required assistance
** Co remains on track to complete its rolling U.S. approval filing for miv-cel in Q4 2026
** Separate follow-up data in myasthenia gravis, a muscle-weakness disease, showed benefits lasting up to 1.5 years; late-stage enrollment set to finish in mid-2027
** As of last close, stock down ~25% YTD
 
  
 

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))